Viewing nowCombinationNanumed Tablet 50/850 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Korea Hu-Tech Pharmaceuticals Co., Ltd.

MFDS item code 202204601 · Approved 2022.12.21 · Insurance code 649105700
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medicine helps effectively control blood sugar in patients with type 2 diabetes who have difficulty controlling it through diet and exercise. Sitagliptin and Metformin work together to help maintain stable blood sugar levels. Continuous use can improve blood sugar control and significantly aid in diabetes management. Thus, this medicine is used to improve blood sugar control in patients with type 2 diabetes.
The dose of this medicine for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine is determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug treatment who cannot achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) together with the patient's current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg); the initial dose of metformin should be based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medicine is administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia caused by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to assess the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in treatment for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, since the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
This medicine is an antidiabetic agent containing Sitagliptin and Metformin. First, during the intake of this medicine, serious allergic reactions may occur, so caution is advised. If symptoms such as skin rash, hives, difficulty breathing, or swelling of the face or neck occur, discontinue use immediately and consult a physician. Additionally, there have been reports of severe side effects such as acute pancreatitis, which is inflammation of the pancreas. Therefore, if sudden abdominal pain, vomiting, or nausea occurs, you should visit a hospital immediately. This medicine should not be administered to patients with impaired kidney function. It may be dangerous to take this medicine if there are conditions such as poor kidney function, acute renal failure, dehydration, severe infections, or heart failure, so it is essential to consult with a physician. Women who are pregnant or likely to become pregnant, as well as nursing women, should not take this medicine, and safety and efficacy have not been established for children under 18 years of age. This medicine may cause hypoglycemia, so particularly patients taking it with other hypoglycemic agents or insulin should be aware of the symptoms of hypoglycemia. Symptoms of hypoglycemia include dizziness, cold sweat, severe fatigue, and confusion, and if these symptoms occur, immediate intake of sugar or consultation with healthcare professionals is necessary. Moreover, this medicine can induce lactic acidosis, a rare but potentially fatal metabolic disorder, so if sudden difficulty in breathing, muscle pain, lethargy, or abdominal pain occurs, you must go to the hospital immediately. Before undergoing surgery or tests using radioactive iodine contrast agents, this medicine should be temporarily discontinued, and it should be resumed only after confirming that kidney function is normal post-surgery. It is best to avoid alcohol intake while taking this medicine, as excessive alcohol consumption can be particularly dangerous. Regular blood tests to monitor kidney function and vitamin B12 levels are important, as vitamin B12 deficiency may occur; supplementation may be necessary if needed. Finally, during the use of this medicine, you should maintain a consistent diet and exercise regimen, and regularly monitor blood glucose and kidney function to ensure safe and effective treatment.
Not everyone experiences these, and they can vary from person to person.
This medicine should be stored in a sealed container to prevent air exposure, at a room temperature between 1°C and 30°C. Proper storage will help maintain the efficacy of the medication for a longer period.
Oval film-coated tablets that are dark pink in color
56 tablets/box [(14 tablets/PTP×4)], 30 tablets/bottle, 200 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Korea Hu-Tech Pharmaceuticals Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.